Статья
НАРУШЕНИЯ РИТМА СЕРДЦА ПРИ МЕТАБОЛИЧЕСКОМ СИНДРОМЕ
Излагаются современные представления о метаболическом синдроме, критериях, используемых при постановке данного диагноза, особенностях медикаментозной терапии различных компонентов метаболического синдрома, а также сведения о его влиянии на частоту возникновения нарушений ритма сердца и риск развития внезапной аритмической смерти
1. Gersh B.J., Tsang T.S.M., Seward J.B. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Transaction of the American clinical and climatological association 2004;115:P.149-160.
2. Ash-Bernal R., Peterson L.R. The cardiometabolic syndrome and cardiovascular disease. J Cardiometab Syndr 2006;1:25-28.
3. Umetani K., Kodama Y., Nakamura T. et al. High Prevalence of Paroxysmal Atrial Fibrillation and/or Atrial Flutter in Metabolic Syndrome. Circ J 2007;71:252-255.
4. H.Watanabe, N.Tanabe, T.Watanabe et al. Metabolic Syndrome and Risk of Development of Atrial Fibrillation. The Niigata Preventive Medicine Study. Circulation 2008; 117: I255-1260.
5. Nicolaou V.N., Papadakis J.E., Karatzis F.N. et al. Impact of the metabolic syndrome on atrial size in patients with new-onset atrial fibrillation. Angiology 2007;58 (1):21-25.
6. Echahidi N., Mohty D., Pibarot P. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007; 116 (11): I213-1219.
7. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001;321 (4):225-236.
8. Bray G.A., Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006;29 (1):109-117.
9. Empana J.-P., Duciemetiere P., Balkau B., Jouven X. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I. EHJ 2007;28(9):1149-1154.
10. Soydinc S., Davutoglu V., Akcay M. Uncomplicated metabolic syndrome is associated with prolonged electrocardiographic QTc interval and QTc dispersion. Ann Noninvasive Electrocardiol 2006;11(4):313-317.
11. Lown B., Verrier R.L. Neural activity and ventricular fibrillation. N Engl J Med 1976;294(21):1165-1170.
12. Verrier R.L., Antzelevitch C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 2004;19(1):2-11.
13. Park S.K., Schwartz J., Weisskopf M. et al. Low-Level Lead Exposure, Metabolic Syndrome, and Heart Rate Variability: The VA Normative Aging Study. Environ Health Perspect 2006;114(11):1718-1724.
14. Guidelines for the Management of Arterial Hypertension. EHJ 2007; 28: 1462-1536.
15. Miranda P.J., DeFronzo R.A., Califf R.M., Gryton J.R. Metabolic syndrome: definition, pathophysiology and mechanisms. Am Heart J 2005; 149: 33-45.
16. Ardern C.I., Janssen I., Ross R., Katzmarzyk P.T. Development of health-related waist circumference thresholds within BMI categories. Obes Res 2004;12:1094-1103.
17. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539-553.
18. National Cholesterol Education Program, Adult Treatment Panel III, 2001. JAMA 2001; 285: 2486-2497.
19. Lakka H.M., Laaksonen D.E., Lakka T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 27092716.
20. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;16;287(3):356-359.
21. Evans R.M., Barish G.D.,Wang Y.U. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
22. Диагностика и лечение метаболического синдрома. Российские рекомендации. Приложение №2 к журналу «Кардиоваскулярная терапия и профилактика» 2007; 6: 1 - 26.
23. Kershaw E.E., Flier J.S. Adipose tissue as endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
24. Lindholm L.H., Persson M., Alaupovic P., e.a. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-1574.
25. Amos A.F., McCarty D.J., Zimmet P. The rising global burdens of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 4(5): S7.
26. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, III пересмотр. Приложение №3 к журналу «Кардиоваскулярная терапия и профилактика» 2007; 6: 1 - 44.
27. Ryden L., Standi E., e.a. Diabetes, Pre-diabetes and Cardiovascular Diseases. EHJ, 2007; 28: 88-136.
28. J.T.Nguyen, D.G.Benditt. Atrial Fibrillation Susceptibility in Metabolic Syndrome. Simply the Sum of Its Parts? Circulation 2008; 117: I249-1251.
29. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. EHJ, 2006;27:1979-2030.
30. ACC/AHA/ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary. EHJ, 2006; 27: 2099-2140.